Amag Pharmaceuticals (AMAG) 21.04 $AMAG Should You Get

New Post Public Reply Private Reply Replies (0) Message Board

Jun 12, 2016 at 2:22 AM

Amag Pharmaceuticals (AMAG) 21.04 $AMAG

Should You Get Rid of AMAG Pharmaceuticals (AMAG) Now?
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:54AM CDT
AMAG Pharmaceuticals has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off.
ANIP: 52.05 (-1.64), AMAG: 21.04 (-0.82)

AMAG Pharmaceuticals to Present at Upcoming Investor Conferences
GlobeNewswire - Wed May 25, 7:08AM CDT
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will discuss AMAG's business and financial outlook, strategy and growth prospects at the following investor conferences taking place in June 2016.
AMAG: 21.04 (-0.82)

Why Investors Still See Value in Alkermes, AMAG Pharmaceuticals, IDEXX Laboratories and Atossa Genetics?
PR Newswire - Thu May 19, 7:50AM CDT
The equities market is never short of surprises, and one sector that is always abounding of surprises is without doubt the Healthcare space. ActiveWallSt.com has uncovered four stocks in the Healthcare sector ahead of today's trading session: Alkermes PLC (NASDAQ: ALKS), AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), IDEXX Laboratories Inc. (NASDAQ: IDXX), and Atossa Genetics Inc. (NASDAQ: ATOS). Sign up for your complimentary alerts at:
ATOS: 0.31 (-0.01), AMAG: 21.04 (-0.82), IDXX: 88.88 (-1.37), ALKS: 42.65 (-1.17)

New Strong Sell Stocks for May 19th
Swarup Gupta - Zacks Investment Research - Thu May 19, 7:45AM CDT
5 fresh stock additions to the Zacks Rank #5 (Strong Sell) List for Thursday
UEPS: 10.51 (-0.22), PLM: 0.80 (-0.02), MTGE: 15.99 (-0.07), WY: 30.59 (+0.22), AMAG: 21.04 (-0.82)

AMAG Pharmaceuticals Announces 2016 Analyst Day
GlobeNewswire - Thu May 19, 7:00AM CDT
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), a specialty pharmaceutical company with a diverse portfolio of products in the areas of maternal health, anemia management and cancer supportive care, today announced that it will host an Analyst Day in New York City on Wednesday, June 1, 2016. The event will start at 8:30 a.m. and conclude at approximately 12:00 p.m. ET.
AMAG: 21.04 (-0.82)

AMAG Pharmaceuticals Has Returned 19.3% Since SmarTrend Recommendation (AMAG)
Comtex SmarTrend(R) - Wed May 18, 1:21AM CDT
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on May 3rd, 2016 at $23.23. In approximately 2 weeks, AMAG Pharmaceuticals has returned 19.29% as of today's recent price of $18.75.
AMAG: 21.04 (-0.82)

Downgrade Alert for AMAG Pharmaceuticals (AMAG)
Comtex SmarTrend(R) - Thu May 05, 3:36AM CDT
AMAG Pharmaceuticals (NASDAQ:AMAG) was downgraded from Outperform to Market Perform at Raymond James today. The stock closed yesterday at $19.55 on volume of 4.3 million shares, above average daily volume of 1.0 million. AMAG Pharmaceuticals share prices have moved between a 52-week high of $77.73 and a 52-week low of $20.22 and closed yesterday at -3% above that low price at $19.55 per share. Over the past week, the 200-day moving average (MA) has gone down 2.2% while the 50-day MA has declined 0.7%.
AMAG: 21.04 (-0.82)

AMAG Pharmaceuticals Reports First Quarter 2016 Financial Results
GlobeNewswire - Tue May 03, 6:00AM CDT
-- First quarter 2016 non-GAAP product revenue increased 52% to $117.6 million
AMAG: 21.04 (-0.82)

AMAG Pharmaceuticals to Participate in the Deutsche Bank 41st Annual Healthcare Conference
GlobeNewswire - Wed Apr 27, 7:02AM CDT
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will participate in an analyst-led fireside chat at the Deutsche Bank 41 Annual Healthcare Conference on Wednesday, May 4, 2016 at 8:40 a.m. ET in Boston.
DB: 15.74 (-0.97), AMAG: 21.04 (-0.82)

AMAG Pharmaceuticals to Host Conference Call on May 3, 2016 at 8:00 a.m. ET to Discuss Financial Results for the First Quarter Ended March 31, 2016
GlobeNewswire - Thu Apr 21, 7:03AM CDT
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced it will report unaudited consolidated financial results for the first quarter ended March 31, 2016 before the U.S. financial markets open on Tuesday, May 3, 2016. The announcement will be followed by a conference call and webcast with slides at 8:00 a.m. ET, during which management will provide an update on recent developments and discuss the company's first quarter 2016 financial and operating results.
AMAG: 21.04 (-0.82)

Gilead Presents Multiple HCV and HBV Data at Liver Congress
Zacks Equity Research - Zacks Investment Research - Mon Apr 18, 12:59PM CDT
Gilead Sciences (GILD) presented results from several phase II and phase III studies for the treatment of HCV and HBV infection at The International Liver Congress.
EBS: 42.30 (-1.19), GILD: 84.45 (-1.32), AMAG: 21.04 (-0.82), ANIK: 49.16 (+0.24)

Synta Stock Up on Merger Deal with Madrigal Pharmaceuticals
Zacks Equity Research - Zacks Investment Research - Fri Apr 15, 10:30AM CDT
Synta (SNTA) announced all-stock merger transaction with Madrigal Pharmaceuticals to create a company focused on cardiovascular-metabolic diseases and NASH.
SNTA: 0.35 (-0.01), EBS: 42.30 (-1.19), ICPT: 150.66 (-3.56), AMAG: 21.04 (-0.82)

Intrexon (XON) Gains Following Deals with Two Startups
Zacks Equity Research - Zacks Investment Research - Thu Apr 14, 2:40PM CDT
Intrexon's (XON) shares gained after the company announced exclusive channel collaborations with a couple of Harvest Intrexon Enterprise Fund-backed startups.
EBS: 42.30 (-1.19), FCSC: 1.17 (-0.07), XON: 25.27 (+0.14), AMAG: 21.04 (-0.82)

Merck Offers Positive Data from Comparative Trial on Zepatier
Zacks Equity Research - Zacks Investment Research - Thu Apr 14, 10:20AM CDT
Merck (MRK) announced results from a phase III study which compared Zepatier to a regimen of Gilead's Sovaldi plus peginterferon and ribavirin.
EBS: 42.30 (-1.19), GILD: 84.45 (-1.32), MRK: 56.81 (-0.37), AMAG: 21.04 (-0.82)

Arena (ARNA) Gains, Pain Drug Positive in Early Stage Study
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 12:00PM CDT
Arena (ARNA) announced favorable results from a phase Ib study on its pain candidate, APD371.
EBS: 42.30 (-1.19), AMAG: 21.04 (-0.82), ANIK: 49.16 (+0.24), ARNA: 1.99 (-0.07)

Repros Reveals Positive Data on Proellex for Uterine Fibroids
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 11:30AM CDT
Repros (RPRX) reported positive data from a phase IIb study on Proellex (vaginal administration) for the treatment of women suffering from uterine fibroids.
EBS: 42.30 (-1.19), RPRX: 1.70 (-0.08), AMAG: 21.04 (-0.82), ANIK: 49.16 (+0.24)

Valeant (VRX) Receives Notice of Default: Stock in Trouble?
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 10:50AM CDT
Valeant Pharmaceuticals International, Inc. (VRX) announced that it has received a notice of default from its debtors.
VRX: 24.14 (-1.34), ARQL: 1.78 (unch), SCMP: 11.70 (-0.27), AMAG: 21.04 (-0.82)

Horizon Pharma Plunges on Bleak Q1 and 1H16 Guidance
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 10:40AM CDT
Horizon Pharma's (HZNP) shares tumbled 26.3%; the company revealed net sales and adjusted EBITDA expectations for the first quarter and first half of 2016.
GILD: 84.45 (-1.32), HZNP: 17.88 (-0.65), AMAG: 21.04 (-0.82), ANIK: 49.16 (+0.24)

Regeneron, Intellia Strike Deal for CRISPR/Cas Platform
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 3:55PM CDT
Regeneron (REGN) entered into a six-year licensing and collaboration agreement with Intellia Therapeutics to develop drugs using gene-editing technology CRISPR/Cas9.
EBS: 42.30 (-1.19), AZN: 27.97 (-0.99), AMAG: 21.04 (-0.82), REGN: 372.03 (-9.05)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rachel Noble Joins AGS: Signals Strategy Shift

A Tactical Addition to American Global Strategies The chessboard of global security just saw a savvy new player join American Global Strategies (AGS). Rachel Noble, a name that echoes through the halls of Australia's national security apparatus, has joined AGS as Senior Advisor. This isn't your garden-variety hire—this is a strategic power move. From Down Under to the...

Boosting Employability: English Skills in Italy's Job Market

Tackling Language Barriers in Italy's Workforce If you're looking to make it big in Italy, you're facing a task that demands more than just regional expertise. The working world is no longer bound by borders, and for Italians eyeing international gigs, English fluency is a must-have. While not an absolute ticket to success, grasping English could be your career's booster...

Third Lake Parts Ways with WaterView Retail Center

Third Lake Partners Exits WaterView Retail in Florida Alright, you don't stumble across deals like this every day. Third Lake Partners just tossed the keys to their WaterView Retail Center in St. Petersburg, wrapping up the retail and residential parts under one roof with Walton Street Capital. It only took a cool five years since its completion in 2021, but hey, better...

Longevity Tour Hits East Coast: Brecka's Mission

Bringing Longevity to the East Coast This weekend, something interesting is happening on the East Coast of the U.S. Gary Brecka and his Ultimate Longevity Center (ULC) are holding a series of events in Philadelphia, New York, and Boston. Everything kicks off on November 14th. If the idea of 'live longevity' leaves you scratching your head, don’t worry—I've got you...

Abbisko's PIMJETMI® Gains FDA Nod, Boosting TGCT Treatment

PIMJETMI® Scores FDA Approval, Expanding Global Reach Well, here's something to chew on over your morning coffee—PIMJETMI® (pimicotinib) just snagged the U.S. FDA's blessing to treat tenosynovial giant cell tumor (TGCT), making it another notch on Abbisko Therapeutics' belt. This approval is a strategic home run for Abbisko and their pals at Merck KGaA, Darmstadt,...

Creative Solutions Joins FICO Marketplace, Boosts AI Edge

Creative Solutions and FICO Unite Well, we're diving into some strategic magic today. Creative Solutions International, not just your average marketing agency, has just hopped onto the FICO Marketplace platform. The word on the street is they're shaking things up with their Collections Marketing Platform. It's like giving your old financial letters a whole AI-driven paint...

Envista's $430M Senior Notes: A Market Move Decoded

Envista on the Move with $430M Notes Ever feel like the market's a bit like a rollercoaster with no brakes? That's kind of where we're at with Envista Holdings Corporation (NYSE: NVST) rolling out this new financial play. They just priced a hefty $430 million in Senior Notes at a solid 6.250% due 2033. In terms of the investment world, that's a pretty big splash. The...

McEwen Faces Investigation Amid Declining Production

MUX Investors on Alert as Legal Stakes Rise The gold mining world isn't exactly flooded with excitement these days, and McEwen Inc.'s (NYSE: MUX) latest dealings ain't doing much to brighten up the scenery. When their third-quarter gold output took a nosedive—a 23% drop to be exact—it caught more eyes than a bull market will. Production Guidance in Question Now,...

Kemin Unveils LYSOFORTE ENFUSIO at EuroTier 2026

Rollin' up to EuroTier 2026 with all its buzz—a place where big players in livestock production flex their muscles—Kemin Industries dropped a new ace in the feed deck: LYSOFORTE ENFUSIO. They're betting this bad boy will shake things up for poultry and pig nutritionists looking to maximize what's already on their plate without piling on more grain or feed costs....

A Gentle Stake: Colts Neck's Rural Fight Ahead

By Ryan Hughes Updated Nov 10, 2026 Category News Views 101

Michael Fazio's Gambit in Colts Neck If you're not fired up about land deals, you should be now. Michael Fazio, the owner of Synergy Stables in Colts Neck, New Jersey, is laying his cards on the table with a proposition for preserving the integrity of the township's rural landscape. Rather than cashing in on monstrous offers for high-density housing, Fazio's plan involves...